Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2013;8(1):e52512.
doi: 10.1371/journal.pone.0052512. Epub 2013 Jan 11.

24 month longitudinal data in ambulant boys with Duchenne muscular dystrophy

Affiliations
Multicenter Study

24 month longitudinal data in ambulant boys with Duchenne muscular dystrophy

Elena Stacy Mazzone et al. PLoS One. 2013.

Erratum in

  • PLoS One. 2013;8(11). doi:10.1371/annotation/cbe611fe-cda9-4d98-9574-0ac18e109daa

Abstract

Objectives: The aim of the study was i) to assess the spectrum of changes over 24 months in ambulant boys affected by Duchenne muscular dystrophy, ii) to establish the difference between the first and the second year results and iii) to identify possible early markers of loss of ambulation.

Methods: One hundred and thirteen patients (age range 4.1-17, mean 8.2) fulfilled the inclusion criteria, 67 of the 113 were on daily and 40 on intermittent steroids, while 6 were not on steroids. All were assessed using the 6 Minute Walk Test (6MWT), the North Star Ambulatory Assessment (NSAA) and timed test.

Results: On the 6MWT there was an average overall decline of -22.7 (SD 81.0) in the first year and of -64.7 (SD 123.1) in the second year. On the NSAA the average overall decline was of -1.86 (SD 4.21) in the first year and of -2.98 (SD 5.19) in the second year. Fourteen children lost ambulation, one in the first year and the other 13 in the second year of the study. A distance of at least 330 meters on the 6MWT, or a NSAA score of 18 at baseline reduced significantly the risk of losing ambulation within 2 years.

Conclusions: These results can be of help at the time of using inclusion criteria for a study in ambulant patients in order to minimize the risk of patients who may lose ambulation within the time of the trial.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: E. Mazzone and Dr. Pane report no disclosures. Dr. Sormani serves on a scientific advisory board for Biogen Idec.; has received funding for travel or speaker honoraria from Merck Serono; serves as consultant for Merck Serono, Actelion Pharmaceuticals Lts. Biogen Idec, and Synthon; and serves on the speakers’ bureaus of Teva Pharmaceutical Industries Ltd., Merck Serono, and Biogen Idec. Dr. Scalise, Dr. Berardinelli, Dr Messina, Dr. Torrente, Dr. D’Amico, Dr. Doglio, Dr. Viggiano, Dr. D’Ambrosio, F. Cavallaro, S. Frosini, Dr. Bello, Dr. Bonfiglio, R. De Sanctis, E. Rolle, Dr. Bianco, Dr. Magri, F. Rossi, and Dr. Vasco report no disclosures. Dr. Vita serves as an Associate Editor for Neurological Sciences. M.C. Motta, Dr. Donati and Dr. Sacchini report no disclosures. Dr. Mongini has received funding for travel from Genzyme Corporation; and has received research support from AIFA (Italian Government Drug Agency) and Telethon Italy. Dr. Pini and Dr. Battini report no disclosures. Dr. Pegoraro has served on a scientific advisory board for BioMarin Pharmaceutical Inc.; has received funding for travel from Genzyme Corporation; and has received speaker honoraria from MedaPharma; and receives research support from Wellstone and Telethon Italy. Dr. Previtali, Dr. Bruno and Dr. Politano report no disclosures. Dr. Comi is site PI for the PTC extension study of Ataluren in DMD, for the TROPHOS clinical trial on SMA and for the GSK study on exon skipping; receives research support from Telethon Italy and SMA Europe. Dr. Bertini is site PI for the PTC extension study of Ataluren in DMD, for the TROPHOS clinical trial on SMA and for the GSK study on exon skipping. He also receives funds from the Italian Telethon, the Italian Ministry of Health and SMA Europe for observational studies on outcome measures. Dr. Mercuri is site PI for the PTC extension study of Ataluren in DMD, for the TROPHOS clinical trial on SMA and for the GSK study on exon skipping. He also receives funds from the Italian Telethon and SMA Europe. He has acted as advisory board for Shire and PTC Therapeutics, Inc, Prosensa. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.

Figures

Figure 1
Figure 1. Mean changes in 6MWT and in NSAA scores in patients below the age of 7 years at baseline (grey line) and above (black line).
Figure 2
Figure 2. Risk of losing ambulation within 2 years in relation to different cut-off points of 6MWD and NSAA scores at baseline.

References

    1. McDonald CM, Henricson EK, Han JJ, Abresch RT, Nicorici A, et al. (2010) The 6-minute walk test as a new outcome measure in Duchenne muscular dystrophy. Muscle Nerve 41: 500–510. - PubMed
    1. Henricson E, Abresch R, Han JJ, Nicorici A, Goude Keller E, et al. Percent-Predicted 6-Minute Walk Distance in Duchenne Muscular Dystrophy to Account for Maturational Influences. PLoS Curr 4: RRN1297. - PMC - PubMed
    1. Mazzone E, Martinelli D, Berardinelli A, Messina S, D’Amico A, et al. (2010) North Star Ambulatory Assessment, 6-minute walk test and timed items in ambulant boys with Duchenne muscular dystrophy. Neuromuscul Disord 20: 712–716. - PubMed
    1. Mazzone E, Vasco G, Sormani MP, Torrente Y, Berardinelli A, et al. (2011) Functional changes in Duchenne muscular dystrophy: a 12-month longitudinal cohort study. Neurology 77: 250–256. - PubMed
    1. Bushby K, Connor E (2011) Clinical outcome measures for trials in Duchenne muscular dystrophy: report from International Working Group meetings. Clin Invest 1: 1217–1235. - PMC - PubMed

Publication types

MeSH terms